Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Arginase deficiency is a rare autosomal recessive amino acid metabolism disorder characterized clinically by variable degrees of hyperammonemia, developing from about 3 years of age, and leading to progressive loss of developmental milestones and spasticity in the absence of treatment.
Features include always present findings: Cholestasis, Shrinkage of the cerebellum (cerebellar atrophy), Enlarged liver (hepatomegaly), and Spastic gait and others; and very common findings: Diaminoaciduria, Global developmental delay, Atypical behavior, and Abnormal speech pattern and others. 28 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 11 | Seizure, Spastic gait, Irritability |
ARG1 encodes arginase 1 (322 aa). Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathway... Highest expression in Liver (400.9 TPM) and Whole Blood (140.7 TPM).
Arginase deficiency is caused by mutations in the ARG1 gene on chromosome 6.
ARG1 is classified as a druggable target (Enzyme category) with score 5.0.
Suggestive Findings
Scenario 1. Abnormal newborn screening (NBS) result
NBS for arginase deficiency is primarily based on quantification of the analyte arginine on dried blood spots.
Arginine values above the cutoff reported by the screening laboratory are considered positive and require follow-up biochemical testing (see Preliminary laboratory findings below).
No approved treatments are currently available for arginase deficiency. The disease remains an area of unmet medical need.
No consensus clinical management guidelines for arginase deficiency have been published. However, general guidelines for the management of urea cycle disorders are available . Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with arginase deficiency, the following evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 2. Recommended Evaluations Following Initial Diagnosis in Individuals with Arginase Deficiency Evaluation | Comment Obtain plasma ammonia, amino acid profile, guanidinoacetate, liver function tests.1 | Consultation w/metabolic physician / biochemical geneticist Gastroenterology / nutrition / feeding team eval | • To incl eval of aspiration risk nutritional status • Consultation w/metabolic dietitian • Consider eval for gastrostomy tube placement in those unable to meet nutritional needs orally. Developmental assessment | Consider referral to developmental pediatrician. Neurologic eval | Consider referral to neurologist if spasticity is present or seizures are suspected. Musculoskeletal eval | To assess for secondary joint contractures lordosis. Consider referral to rehabilitation medicine. 1. Albumin, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, prothrombin time (PT), and partial thromboplastin time (PTT). Treatment of Manifestations The management of individuals with arginase deficiency should closely mirror that described in the Urea Cycle Disorders Overview, with one caveat: individuals with arginase deficiency are less prone to episodes of hyperammonemia and when present, hyperammonemia is more likely to respond to conservative management such as intravenous fluid administration. However, the individual who is comatose and encephalopathic is at high risk for severe brain damage and should be treated accordingly. Arginine supplementation is obviously contraindicated. Table 3. Routine Outpatient Management in Individuals with Arginase Deficiency
Regular follow up at intervals determined by age and degree of metabolic stability is recommended . Table 8. Recommended Surveillance for Individuals with Arginase Deficiency
Manifestation/Monitoring |
|---|
4 clinical trials registered, 2 recruiting. Interventions under study include other interventions and medical devices. Pipeline includes 1 NA. Research is sponsored by a mix of industry and academic institutions.
88 publications have been identified in PubMed for arginase deficiency. Research spans Basic Science / Preclinical (57%), Gene Therapy / Novel Therapeutics (10%), and Epidemiology / Natural History (9%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 50 |
Data assembled from 9 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Digestive system | 6 | Cholestasis, Enlarged liver (hepatomegaly), Anorexia |
Muscles | 2 | Shrinkage of the cerebellum (cerebellar atrophy), Frequent falls |
Growth and development | 1 | Postnatal growth retardation |
To date, more than 260 individuals with arginase deficiency have been identified [; ; ; ; ; ; ; ; Author, personal observation]. The following description of the phenotypic features associated with this condition is based primarily on individuals with severe disease. It should be noted that a phenotypic spectrum exists, and mildly affected individuals exhibit less severe features. Individuals treated from birth (as a result either of newborn screening or of having an affected older sib) appear to have minimal symptoms . Growth and feeding. Most commonly, growth at birth and through early childhood is normal.
Source: GeneReviews — "Arginase Deficiency"
Genotype-phenotype correlations indicate that the amount of residual enzyme activity modulates the phenotype . Severe disease is associated with:
Homozygosity or compound heterozygosity for predicted loss-of-function variants such as , , , and ;
Missense changes such as or when homozygous or in combination with another severe allele.
Source: GeneReviews — "Arginase Deficiency"
Source: GeneReviews — "Arginase Deficiency"
Hyperammonemia. Arginase is the sixth and final enzyme of the eight known steps in the urea cycle. See Urea Cycle Disorders Overview for approaches to distinguish:
Other causes of hyperammonemia from a urea cycle disorder; and
The differences between the urea cycle disorders themselves.
Source: GeneReviews — "Arginase Deficiency"
Genetic testing for ARG1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for arginase deficiency has been reported in the published literature.
Principle | Treatment | Consideration/Other |
|---|---|---|
Acute Outpatient Management in Individuals with Arginase Deficiency Manifestation/Concern | Treatment | Consideration/Other Mildly catabolism1 |
Fever | Administration of antipyretics (acetaminophen, ibuprofen) if temperatures rises 38.5C | — |
Occasional vomiting | Antiemetics | 1. Fever; vomiting, diarrhea, dehydration Some centers advocate reducing natural protein intake to zero or to 50% of the normal prescribed regimen for short periods (24-48 hours) in the outpatient setting during intercurrent illness. |
Acute Inpatient Management in Individuals with Arginase Deficiency Manifestation/Concern | Treatment | Consideration/Other Hyperammonemia (mild to moderate) |
Source: GeneReviews — "Arginase Deficiency"
Valproic acid should be avoided as it exacerbates hyperammonemia in urea cycle defects and other inborn errors of metabolism .
Source: GeneReviews — "Arginase Deficiency"
A clinical trial for enzyme replacement therapy using pegylated synthetic human arginase I is currently under way (Clinical Trials Identifier NCT03921541). A variety of genomic therapies are under investigation including mRNA therapy , ARG1 gene editing , and viral-mediated gene therapy . Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "Arginase Deficiency"
4 trials found
Evaluation
Frequency |
|---|
control | Plasma ammonia, amino acid profile, nutritional monitoring labs | At least 1x/mo for 1st yr of life; thereafter per metabolic specialist Guanidinoacetate |
Poor growth | Monitor growth | At each visit |
Developmental delay | Monitor developmental milestones | At each visit in those age 18 yrs Neuropsychological testing using age-appropriate standardized assessment batteries |
deterioration1 | Neurologic eval | At each visit2 Persistent hepatic synthetic function |
abnormalities | Liver function tests3 | Every 6-12 mos |
Quality of life | Standardized quality of life assessment tools for affected persons parents/caregivers | As needed 1. Developmental stagnation and/or regression; seizures; spasticity; development of joint contractures 2. |
Source: GeneReviews — "Arginase Deficiency"
Phenotype severity distribution: 9 always present features, 5 very common features, 5 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
New treatment approaches | 9 | 10% |
Disease patterns and progression | 8 | 9% |
Patient case studies | 7 | 8% |
Testing and diagnosis research | 5 | 6% |
Clinical study results | 5 | 6% |
Research summaries | 3 | 3% |
Other research | 1 | 1% |
Fan S (2026). [PMID: 41992869](https://pubmed.ncbi.nlm.nih.gov/41992869/). *J Agric Food Chem*. [Gene Therapy / Novel Therapeutics]
Sun B (孙北辰) (2026). [PMID: 42063407](https://pubmed.ncbi.nlm.nih.gov/42063407/). *Circ Res*. [Basic Science / Preclinical]
Kerndl M (2026). [PMID: 42151478](https://pubmed.ncbi.nlm.nih.gov/42151478/). *Nat Immunol*. [Basic Science / Preclinical]
Chung SF (2026). [PMID: 41846479](https://pubmed.ncbi.nlm.nih.gov/41846479/). *Anal Chem*. [Diagnostic / Biomarker]
Lee JS (2026). [PMID: 41871721](https://pubmed.ncbi.nlm.nih.gov/41871721/). *Biochem Pharmacol*. [Basic Science / Preclinical]
Faraguna MC (2026). [PMID: 42194135](https://pubmed.ncbi.nlm.nih.gov/42194135/). *Children (Basel)*. [Clinical Trial Publication]
Unknown (2026). [PMID: 42060774](https://pubmed.ncbi.nlm.nih.gov/42060774/). *Unknown Journal*. [Review / Meta-Analysis]
Castellanos-Pinedo F (2026). [PMID: 41911966](https://pubmed.ncbi.nlm.nih.gov/41911966/). *Neurologia (Engl Ed)*. [Other]
Fry L (2026). [PMID: 41805192](https://pubmed.ncbi.nlm.nih.gov/41805192/). *mBio*. [Basic Science / Preclinical]
Xie Z (2026). [PMID: 41702447](https://pubmed.ncbi.nlm.nih.gov/41702447/). *Cancer letters*. [Basic Science / Preclinical]
AI-curated news mentioning arginase deficiency
Updated Jun 8, 2026
A recent study published in PubMed highlights the prevalence, disease onset, and clinical outcomes of arginase 1 deficiency across Germany, Austria, and Switzerland. This cross-border surveillance provides valuable insights into the disease's impact on affected individuals.
A novel hybrid piggyBac AAV-transposon and LNP-transposase system demonstrates a 100-fold dose reduction for treating arginase deficiency compared to traditional AAV methods. This breakthrough could enhance treatment efficacy and reduce costs for patients.
A recent study published in PubMed provides insights into the clinical characteristics and natural history of arginase 1 deficiency, based on data from international clinical trials. This research enhances understanding of the disease's progression and patient outcomes.